Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
104
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Combination of 99mTc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study

Ping Li1 Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of China;2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China
,
Chang Liu4 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;5 Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, Shanghai, People’s Republic of China;6 Shanghai Engineering Research Center for Molecular Imaging Probes, Shanghai, People’s Republic of China
,
Shuang Wu2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China;7 Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, People’s Republic of China
,
Lin Deng2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China;8 Department of Radiology, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of China
,
Guangyuan Zhang2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China;8 Department of Radiology, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of China
,
Xin Cai1 Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of China;2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China
,
Silong Hu4 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;5 Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, Shanghai, People’s Republic of China;6 Shanghai Engineering Research Center for Molecular Imaging Probes, Shanghai, People’s Republic of China
,
Jingyi Cheng2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China;6 Shanghai Engineering Research Center for Molecular Imaging Probes, Shanghai, People’s Republic of China;9 Department of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, People’s Republic of China
,
Xiaoping Xu4 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;5 Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, Shanghai, People’s Republic of China;6 Shanghai Engineering Research Center for Molecular Imaging Probes, Shanghai, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-9656-6233
ORCID Icon,
Bin Wu2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China;10 Department of Radiology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, People’s Republic of China
,
Xiaomao Guo2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of China;7 Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, People’s Republic of China
,
Yingjian Zhang4 Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China;5 Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, Shanghai, People’s Republic of China;6 Shanghai Engineering Research Center for Molecular Imaging Probes, Shanghai, People’s Republic of China
,
Shen Fu5 Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, Shanghai, People’s Republic of China;11 Department of Radiation Oncology, Shanghai Concord Cancer Hospital, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
&
Qing Zhang1 Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, People’s Republic of China;2 Shanghai Key Laboratory of Radiation Oncology, Shanghai, People’s Republic of China;3 Shanghai Engineering Research Center of Proton and Heavy ion Radiation Therapy, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 2191-2199 | Published online: 03 Mar 2021

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Luca Filippi, Barbara Palumbo, Viviana Frantellizzi, Susanna Nuvoli, Giuseppe De Vincentis, Angela Spanu & Orazio Schillaci. (2022) Prostate-specific membrane antigen-directed imaging and radioguided surgery with single-photon emission computed tomography: state of the art and future outlook. Expert Review of Medical Devices 19:11, pages 815-824.
Read now

Articles from other publishers (3)

Cristina Bolzati, Carolina Gobbi, Guillermina Ferro-Flores, Sofia Turato, Blanca Ocampo-Garcia, Debora Carpanese, Cristina Marzano, Barbara Spolaore, Giulio Fracasso, Antonio Rosato & Laura Meléndez-Alafort. (2023) Development and Characterization of 99mTc-scFvD2B as a Potential Radiopharmaceutical for SPECT Imaging of Prostate Cancer. International Journal of Molecular Sciences 25:1, pages 492.
Crossref
Viktoriia K. Tishchenko, Vasily M. Petriev, Oksana P. Vlasova, Andrei A. Pankratov, Natalia B. Morozova, Petr V. Shegai, Sergei A. Ivanov & Andrei D. Kaprin. (2023) 99mTc-Labelled Low Molecular Weight Inhibitors of Prostate-Specific Membrane Antigen. Annals of the Russian academy of medical sciences 77:6, pages 420-436.
Crossref
Sara Brunello, Nicola Salvarese, Debora Carpanese, Carolina Gobbi, Laura Melendez-Alafort & Cristina Bolzati. (2022) A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer. Molecules 27:9, pages 2617.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.